H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Cesca Therapeutics (KOOL) today and set a price target of $1.50. The company’s shares closed yesterday at $0.31, close to its 52-week low of $0.22.
Ramakanth commented:
“We maintain our Buy rating of Cesca Therapeutics and our 12-month price target of $1.50 per share. We derive our price target based on a risk-adjusted NPV analysis of projected product revenues through 2030 assuming a 10% discount rate and 3% terminal growth rate.”
According to TipRanks.com, Ramakanth is a 1-star analyst with an average return of -1.8% and a 33.2% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Leap Therapeutics Inc.
Cesca Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $1.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $4.14 and a one-year low of $0.22. Currently, Cesca Therapeutics has an average volume of 463.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cesca Therapeutics, Inc. engages in the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine. It operates through the Clinical Development Division and Device Division business segments.
